Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med's stock price has increased by 5% on March 27, reaching 53.32 yuan per share, with a total market capitalization of 45.91 billion yuan, and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under China International Capital Corporation (CICC) holds a significant position in Tiger Med. The CICC New Medicine A Fund (006981) held 89,800 shares in the fourth quarter, representing 5.9% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 228,100 yuan today, with a total floating profit of 291,000 yuan during the three-day increase [2][5]. - The CICC New Medicine A Fund was established on May 14, 2019, with a current scale of 68.32 million yuan. Year-to-date, it has experienced a loss of 6.84%, ranking 4,764 out of 5,563 in its category; over the past year, it has gained 8.47%, ranking 3,376 out of 4,429; and since inception, it has achieved a return of 44.49% [2][5]. Fund Manager Information - The fund manager of CICC New Medicine A is Ding Tianyu, who has been in the position for 5 years and 89 days. The total asset size of the fund is 205 million yuan, with the best return during his tenure being 2.35% and the worst return being -30.51% [3][6][7].